Evidence map›Paper›PMID 29196297›Full record

ArticleClinical cancer research : an official journal of the American Association for Cancer Research2018

Acetylsalicylic Acid Governs the Effect of Sorafenib in

Heinz Hammerlindl, Dinoop Ravindran Menon, Sabrina Hammerlindl, Abdullah Al Emran, Joachim Torrano, Katrin Sproesser, Divya Thakkar, Min Xiao, Victoria G Atkinson, Brian Gabrielli and 4 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.0field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 18 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. Inhibition of MEK, a canonical KRAS pathway effector inTranslational lung cancer research · 2018
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 2 countries.

Heinz HammerlindlDermatology Research Centre, The University of Queensland, The University of Queensland Diamantina Institute, Translational Research Institute, Brisbane, Australia.
Dinoop Ravindran Menon *Dermatology Research Centre, The University of Queensland, The University of Queensland Diamantina Institute, Translational Research Institute, Brisbane, Australia.
Sabrina Hammerlindl *Dermatology Research Centre, The University of Queensland, The University of Queensland Diamantina Institute, Translational Research Institute, Brisbane, Australia.
Abdullah Al EmranDermatology Research Centre, The University of Queensland, The University of Queensland Diamantina Institute, Translational Research Institute, Brisbane, Australia.
Joachim TorranoDermatology Research Centre, The University of Queensland, The University of Queensland Diamantina Institute, Translational Research Institute, Brisbane, Australia.
Katrin SproesserThe Wistar Institute, Philadelphia, Pennsylvania.
Divya ThakkarDermatology Research Centre, The University of Queensland, The University of Queensland Diamantina Institute, Translational Research Institute, Brisbane, Australia.
Min XiaoThe Wistar Institute, Philadelphia, Pennsylvania.
Victoria G AtkinsonDivision of Cancer Services, Princess Alexandra Hospital, Brisbane, Australia.
Brian GabrielliMater Medical Research Institute, The University of Queensland, Translational Research Institute, Brisbane, Australia.
Nikolas K HaassThe University of Queensland, The University of Queensland Diamantina Institute, Translational Research Institute, Brisbane, Australia.
Meenhard HerlynThe Wistar Institute, Philadelphia, Pennsylvania.
Clemens KreplerThe Wistar Institute, Philadelphia, Pennsylvania.
Helmut SchaiderDermatology Research Centre, The University of Queensland, The University of Queensland Diamantina Institute, Translational Research Institute, Brisbane, Australia. h.schaider@uq.edu.au.
The Wistar Institute · USPrincess Alexandra Hospital · AU

Funding

Tumor Microenvironment and MetastasisP30CA010815 · NCI · WISTAR INSTITUTE · PI Luis J Montaner · 1985 to 2026
$75.9M
Targeting the MAP and PI3 Kinase Pathways in MelanomaP01CA114046 · NCI · WISTAR INSTITUTE · PI MURPHY, MAUREEN E. · 2008 to 2023
$37.1M
Targeted Combination Therapy for MelanomaP50CA174523 · NCI · WISTAR INSTITUTE · PI HERLYN, MEENHARD F · 2014 to 2018
$11.1M
NCI NIH HHS P01 CA114046NCI NIH HHS P30 CA010815NCI NIH HHS P50 CA174523
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AMP-Activated Protein KinasesAnimalsAntineoplastic Combined Chemotherapy ProtocolsAspirinCell Line, TumorCell ProliferationDrug SynergismExtracellular Signal-Regulated MAP KinasesHumansMiceMutationNeoplasmsProto-Oncogene Proteins B-rafras ProteinsSignal TransductionSorafenibAMP-Activated Protein KinasesAspirinBRAF protein, humanExtracellular Signal-Regulated MAP KinasesProto-Oncogene Proteins B-rafras ProteinsSorafenib

Identifiers

PMID29196297
PMCPMC5844814
OpenAlexW2773816949

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.